<div id="readability-page-1">05:42 PM EST, 12/03/2025 (MT Newswires) -- Apellis (APLS) said Wednesday the New England Journal of Medicine published positive Phase 3 results for Empaveli, its treatment for rare kidney diseases.The study showed a 68% reduction in proteinuria, the presence of an abnormal amount of protein in the urine, at Week 26, along with stabilization of kidney function and reduced C3 staining, the company said.Results were consistent across adults and adolescents, including patients whose disease returned after a transplant. Empaveli is already Food and Drug Administration-approved for patients 12 and older.Shares of the company were up over 1% in after-hours trading. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

APLS

Apellis（APLS）公布了其肾病治疗药物 Empaveli 的积极第三阶段临床试验结果，相关研究发表在《新英格兰医学杂志》上。研究显示，在第 26 周时，蛋白尿减少了 68%，肾功能稳定，C3 染色减少。结果在成年人和青少年中一致，包括移植后患者。Empaveli 已获得 FDA 批准，适用于 12 岁及以上的患者。盘后交易中，股价上涨超过 1%

Apellis 报告其肾病治疗药物 Empaveli 的三期试验结果呈现积极效果